Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Myeloma
•
Hematology
How do you do risk stratification for patients with light chain only MGUS?
Related Questions
Are there specific indications where you would use thalidomide over lenalidomide for treatment of newly diagnosed multiple myeloma?
Are there specific findings that would make you suspicious of IgD or IgE monoclonal gammopathies?
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
Under what circumstances is it okay to initiate treatment for suspected multiple myeloma without a bone marrow biopsy?
Is there a role for CRS prophylaxis with tocilizumab during bispecific T cell engager initiation for myeloma?
How do you monitor multiple myeloma in patients receiving dialysis?
How do you evaluate a patient with MGUS and peripheral neuropathy?
What is your preferred dose and schedule for maintenance drugs post autoHCT for newly diagnosed multiple myeloma?
What clinical or logistical factors influence your choice of anti-CD38 antibody in first line treatment of Multiple Myeloma?
How does one approach maintenance treatment in transplant ineligible patients with newly diagnosed multiple myeloma?
